We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Topline results from a phase 2b/3 clinical trial of ...
Phase 1 data shows sabirnetug (ACU193) is safe, reduces amyloid plaques, and supports ongoing Phase 2 trial for early Alzheimer’s disease. The press release implies that while there were positive ...
Last July, the U.S. Food and Drug Administration (FDA) issued a notable approval for LEQEMBI® (lecanemab-irmb), the first medicine to slow the rate of cognitive decline in certain patients with early ...
Please provide your email address to receive an email when new articles are posted on . Early Alzheimer’s care should include new FDA-approved therapies like lecanemab. The guidance suggests greater ...
Only a small fraction of older adults in the early stages of Alzheimer's disease (AD) meet eligibility criteria to receive treatment with newly approved anti-amyloid drugs, largely due to the presence ...
Anavex Life Sciences Corp. announced significant findings from the ATTENTION-AD trial, indicating that long-term treatment with the oral drug blarcamesine (ANAVEX®2-73) improved cognition and ...
LEADS aims to study 400 adults, ages 40 to 64, who have Alzheimer’s but no autosomal-dominant AD mutation. Some carry FTD or Parkinson's genes. Many likely became amyloid-positive in their 30s. The ...
Early initiation of daily specialized emollient use until 2 months was associated with a reduced incidence of atopic dermatitis development among high-risk infants. Early initiation of daily ...
NEW YORK — Budweiser is trotting out some familiar characters this year in its Super Bowl ad. The perennial NFL championship game marketer is bringing back fan-favorite team of Clydesdale horses and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback